A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

British Journal of Cancer

Volumn 115, Issue 10, 2016, Pages 1206-1214

  Kim, Tae Won ^a   Elme, Anneli ^b   Kusic, Zvonko ^c   Park, Joon Oh ^d   Udrea, Anghel Adrian ^e   Kim, Sun Young ^f   Ahn, Joong Bae ^g   Valencia, Ricardo Villalobos ^h   Krishnan, Srinivasan ⁱ   Bilic, Ante ^j   Manojlovic, Nebojsa ^k   Dong, Jun ^l   Guan, Xuesong ^l   Lofton Day, Catherine ^l   Jung, A Scott ^l   Vrdoljak, Eduard ^m  

^a University of Ulsan   (South Korea)

^b North Estonia Medical Centre   (Estonia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d Samsung Medical Center   (South Korea)

^e Medisprof   (Romania)

^f National Cancer Center   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁱ VHS Medical Centre India   (India)

^j University Hospital Sveti Duh   (Croatia)

^k UNIVERSITY OF DEFENCE   (Serbia)

^l AMGEN INC   (United States)

^m UNIVERSITY HOSPITAL SPLIT   (Croatia)

more..

Author keywords

colorectal; Gastrointestinal cancer; panitumumab; phase 3 trial

Indexed keywords

PANITUMUMAB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN P21; RAS PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; DERMATITIS; EXON; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPOMAGNESEMIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; ONCOGENE RAS; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; SEPSIS; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; CROSSOVER PROCEDURE; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; YOUNG ADULT;

EID: 84991029246     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.309     Document Type: Article

References (23)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
3. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
4. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51: 1243-1252.
5. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, SesbouR, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169.
6. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocaova I, Ruff P, B"asinka-Morawiec M, S makal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034.
7. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocaova I, Ruff P, B"asinka-Morawiec M, S makal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
8. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45: 228-247.
10. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
11. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, CôteJF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
12. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385.
13. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
14. Patterson SD, Peeters M, Siena S, Van Cutsem E, Humblet Y, Van Laethem J-L, Andre T, Tian Y, Sidhu R, Oliner KS (2013) Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). J Clin Oncol 31: abstract 3617.
15. Peeters M, Oliner K, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, AndreT, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD (2015) Analysis of KRAS/NRAS mutations in a phase 3 study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 21: 5469-5479.
16. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, AndreT, Wiezorek J, Reese D, Patterson SD (2013) Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19: 1902-1912.
17. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, AndreT, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713.
18. Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M (2013) An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol 8: 127-136.
19. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15: 569-579.
20. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
21. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 32: 2240-2247.
22. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33: 692-700.
23. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664.